Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

My Favorite Biotech Stock for 2021

By George Budwell - Jan 4, 2021 at 10:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This clinical-stage biotech stock could be a top buyout candidate in 2021.

Biotechs have consistently dominated the list of best-performing stocks over the past two decades. A whopping 32 biotech equities, for instance, generated returns in excess of 300% in 2020. Perhaps the most attractive part of this powerful trend for investors is that several of these companies weren't so-called COVID-19 plays, either. As just one example, Cardiff Oncology, a clinical-stage cancer specialist, produced a jaw-dropping 1,400% return on capital over the whole of 2020.

Which biotech stocks are poised for rocket-like growth in 2021? I have my eye on several names as the new year opens, but my favorite name in biotech this year is Trillium Therapeutics ( TRIL ). Here's why I think this small-cap biotech could be a big winner in 2021. 

A female researcher working at a benchtop.

Image source: Getty Images.

Why is Trillium a possible home run stock?

Trillium sports a truly novel -- yet largely unproven -- immuno-oncology platform. Specifically, the company's anti-cancer compounds both target the CD47 pathway (the "don't eat me" signal) and may also enhance the immune response against certain types of cancer cells.

Another unique aspect of Trillium's drug compounds is that they do not bind to red blood cells, which should reduce the risk of drug-induced anemia, keep the compound from being easily removed by circulating red blood cells, and minimize the potential for interference with transfusion medicine. 

Where do things stand now? Trillium is presently evaluating its two lead compounds -- TTI-621 and TTI-622 -- in a pair of phase 1 dose escalation trials in heavily pre-treated patients with various types of blood cancer. These ongoing trials should provide insight into any dose-limiting toxicities, major safety signals, and perhaps most importantly, the specific indications with the best chance of success in larger trials.

Additionally, Trillium is planning on assessing these CD47 blockade compounds in combination with a variety of other anti-cancer drugs, such as PD-1 inhibitors. Keeping with this theme, the biotech's braintrust recently announced that a full-blown clinical development plan for its lead compounds -- including forthcoming combo studies and solid tumor trials -- would be revealed at some point in 2021. 

The big picture is that the CD47 blockade arena has already attracted several major players. Gilead Sciences ( GILD -0.09% ), for instance, paid a handsome $4.9 billion last year to take out Forty Seven for its anti-CD47 monoclonal antibody magrolimab. And less than six months later, Pfizer ( PFE -5.14% ) agreed to purchase $25 million of Trillum's common stock in a move that may lead to a closer relationship down the road. In short, there is a lot of interest in this emerging wing of immuno-oncology.  

What's Trillium's upside potential in 2021?

By the end of the year, Trillum is expected to provide several key updates on TTI-621's ongoing phase 1 trial in a basket of blood cancers. This trial, in fact, is slated to wrap up by the end of the year. Trillium will also likely roll out a handful of preliminary data drops for TTI-622 -- even though this drug's phase 1 trial isn't scheduled to produce top-line data until early summer of 2022. The long and short of it is that investors should have a fairly solid idea of whether or not this novel immuno-oncology platform is worth advancing into larger trials by the end of the year. 

And if Trillium does indeed have a best-in-class CD47 blockade platform, Pfizer or another oncology giant will almost certainly come calling with a sizable buyout offer, perhaps by the winter of 2021. The fact of the matter is that the trend among big pharma over the past several years has been to identify compounds with a well-differentiated mechanism of action early on in development, and then pay seemingly whatever it takes to add them to the pipeline (see Gilead and Pfizer's litany of recent acquisitions for just a few examples).

Trillium, for its part, undoubtedly has a unique anti-cancer platform capable of attracting a high-dollar tender offer. In fact, my hunch (and it's only a hunch) is that Pfizer will most likely be the first one in line with an offer if either of Trillium's lead compounds yields an attractive safety and efficacy profile. How big of an offer? Well, it's hard to imagine Trillium accepting anything lower than what Gilead paid for Forty Seven last year. In effect, I believe that Trillium's shares sport a 240% upside potential -- or better -- in 2021 via a buyout scenario; again, assuming the clinical side of this equation pans out. 

That being said, this development biotech is a super-risky play due to the early-stage nature of its platform. Cancer drugs have a long history of flaming out in the clinic, and Trillium's CD47 blockade compounds could very well turn out to be duds. In other words, investors shouldn't buy more than they can afford to lose. What's more, it's probably best to keep any potential position on the small side until more data are available for public consumption.      

 
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Trillium Therapeutics Inc. Stock Quote
Trillium Therapeutics Inc.
TRIL
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.48 (-5.14%) $-2.79
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$69.50 (-0.09%) $0.06
Cardiff Oncology, Inc. Stock Quote
Cardiff Oncology, Inc.
CRDF
$5.28 (0.76%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.